These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30019949)

  • 1. Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders.
    Walker LC; Lawrence AJ
    Expert Opin Investig Drugs; 2018 Jul; ():1-14. PubMed ID: 30019949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs for alcohol use disorders: a review of preclinical data.
    Ch'Ng SS; Lawrence AJ
    Expert Opin Investig Drugs; 2018 May; 27(5):459-474. PubMed ID: 29723484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel human laboratory model for screening medications for alcohol use disorder.
    Ho D; Towns B; Grodin EN; Ray LA
    Trials; 2020 Nov; 21(1):947. PubMed ID: 33225963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of ketamine for alcohol use disorder.
    Worrell SD; Gould TJ
    Neurosci Biobehav Rev; 2021 Jul; 126():573-589. PubMed ID: 33989669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies.
    Morley KC; Perry CJ; Watt J; Hurzeler T; Leggio L; Lawrence AJ; Haber P
    Expert Opin Pharmacother; 2021 Jul; 22(10):1291-1303. PubMed ID: 33615945
    [No Abstract]   [Full Text] [Related]  

  • 8. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Epigenetic Mechanisms to Treat Alcohol Use Disorders (AUD).
    Rodriguez FD
    Curr Pharm Des; 2021 Oct; 27(30):3252-3272. PubMed ID: 33535943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimmune signaling in alcohol use disorder.
    Erickson EK; Grantham EK; Warden AS; Harris RA
    Pharmacol Biochem Behav; 2019 Feb; 177():34-60. PubMed ID: 30590091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational crossover randomized trial.
    Haass-Koffler CL; Magill M; Cannella N; Brown JC; Aoun EG; Cioe PA; Sinha R; Swift RM; Ciccocioppo R; Leggio L
    medRxiv; 2023 Jan; ():. PubMed ID: 36711869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLC Neurotransmitter Transporters as Therapeutic Targets for Alcohol Use Disorder: A Narrative Review.
    McColl ER; Piquette-Miller M
    Alcohol Clin Exp Res; 2020 Oct; 44(10):1965-1976. PubMed ID: 32862443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical Frameworks and Mechanistic Aspects of Alcohol Addiction: Alcohol Addiction as a Reward Deficit/Stress Surfeit Disorder.
    Koob GF; Vendruscolo L
    Curr Top Behav Neurosci; 2023 Jul; ():. PubMed ID: 37421551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder.
    Vatsalya V; Verster JC; Sagaram M; Royer AJ; Hu H; Parthasarathy R; Schwandt ML; Kong M; Ramchandani VA; Feng W; Agrawal R; Zhang X; McClain CJ
    Front Psychiatry; 2023; 14():1203362. PubMed ID: 37840804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of neuroimmune modulation on subjective response to alcohol in the natural environment.
    Meredith LR; Grodin EN; Montoya AK; Miranda R; Squeglia LM; Towns B; Evans C; Ray LA
    Alcohol Clin Exp Res; 2022 May; 46(5):876-890. PubMed ID: 35362101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a randomized controlled trial examining the efficacy of oxytocin to enhance alcohol behavioral couple therapy.
    Flanagan JC; Joseph JE; Nietert PJ; Back SE; McCrady BS
    Contemp Clin Trials; 2019 Jul; 82():1-8. PubMed ID: 31063869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder.
    Prajapati SK; Bhaseen S; Krishnamurthy S; Sahu AN
    Neurochem Res; 2020 Feb; 45(2):491-507. PubMed ID: 31898084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Correlates of the Alcohol Use Disorder Pharmacotherapy Response: A Systematic Review of Neuroimaging Studies.
    Florence L; Lassi DLS; Kortas GT; Lima DR; de Azevedo-Marques Périco C; Andrade AG; Torales J; Ventriglio A; De Berardis D; De Aquino JP; Castaldelli-Maia JM
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs currently in Phase II clinical trials for cocaine addiction.
    Kim JH; Lawrence AJ
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1105-22. PubMed ID: 24773297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications for alcohol use disorders: An overview.
    Akbar M; Egli M; Cho YE; Song BJ; Noronha A
    Pharmacol Ther; 2018 May; 185():64-85. PubMed ID: 29191394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.